JERUSALEM Israel-based MediWound has signed a five-year, $112 million contract with the U.S. authority that handles public health medical emergencies to further develop and buy the company's drug treatment for severe burns.
Investment group Clal Biotechnology, which has a 45 percent stake in MediWound, said in a statement that the deal with the Biomedical Advanced Research and Development Authority would raise preparedness for mass-casualty incidents.
02:10 Attorney General's office announces settlement with drug manufacturer9
07:16 Aroldis Chapman, Yankees agree to five-year, $86 million record deal15
07:16 Aroldis Chapman Acquired by Yankees in Five-Year, $86 Million Deal15
06:10 Sources: Carlos Gomez, Rangers agree on 1-year, $11.5 million deal22